Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28965)	6/24/1999 7:13:00 PM
From: bob zagorin	Read Replies (1) \| Respond to of 32384

just got my tc2000 data feeed for the the market close and LGND had a big BOP breakout today on strong volume. as well know, this indicator hasn't been teribly accurate for LGND but this is a marked breakout way up into the greee confirmed by price and Moneystream so perhaps we're seeing the beginning of a run here.

To: bob zagorin who wrote (28965)	6/25/1999 7:35:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

Bob, if you actually went and read the posts I referenced, you will see that I did not confuse panretin and targretin.

To: bob zagorin who wrote (28965)	6/26/1999 8:27:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

bob, I think that LGND's choice of oral Targretin has some significant implications, but I can think of many scenarios, so I'm not sure of how the filing order should be interpreted. I had assumed that oral would be first because the big Targretin markets were for the oral form (breast cancer, psoriasis, and diabetes - although now the likely of a diabetes application for Targretin is greatly reduced). When I talked to Susan Atkins last Aug and heard that the selection of oral or topical Targretin had not been made, I took that as an indication that oral had some problems. At that time, oral Targretin was being tested in diabetes and psoriasis patients and I knew that LGND was also planning a major push for breast cancer (as monotherapy and combination therapy with Tamoxifen in advanced breast cancer patients, and in combination with SERMs like a second generation Evista in pre-clinical test). When I heard that an NDA for topical Targretin might be filed first, I asked if LGND has any ongoing topical trials for Targretin, and I was told that they did not. Thus, there was a major discrepancy here. Oral and topical were in advanced trials for CTCL, and once approved, Targretin could be used off label for other indication. It was clear that LGND was betting on the oral form, yet they were considering filing for the topical form first (as also noted in the Bear Stearns report, which came out shortly after my conversation with IR).